The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Isoprenoids as mediators of the biological effects of statins
Open accessAbstract
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are potent inhibitors of cholesterol biosynthesis.Several large clinical trials have demonstrated the benefits of cholesterol lowering with these agents in the primary and secondary prevention of coronary heart disease.The overall clinical benefits observed with statin therapy, however, appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels.Recent experimental and clinical evidence indicates that some of the cholesterol-independent, or so-called pleiotropic, effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response in the vascular wall.Many of these cholesterolindependent effects reflect statins' ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules.In particular, the inhibition of small GTP-binding proteins Rho, Ras, and Rac, whose proper membrane localization and function are dependent upon isoprenylation, may play an important role in mediating the biological effects of statins. Pharmacological properties of statinsStatins bind to HMG-CoA reductase at nanomolar concentrations, leading to competitive displacement of the natural substrate, HMG-CoA, which binds at micromolar concentrations (1).In addition, inhibition of cholesterol biosynthesis is accompanied by an increase in hepatic LDL receptor, which promotes uptake and clearance of cholesterol from the bloodstream.While all statins inhibit hepatic HMG-CoA reductase to varying degrees, important structural differences exist among the statins that distinguish their lipophilicity, half-life, and potency (2).For example, one of the more potent newer statins, rosuvastatin, is relatively hydrophilic and has a greater number of bonding interactions with the catalytic site of HMG-CoA reductase compared with mevastatin, fluvastatin, simvastatin, cerivastatin, and atorvastatin (1, 3).The lipophilic statins would be expected to penetrate cell membranes more effectively than the more hydrophilic statins, causing more side effects but, at the same time, eliciting more pleiotropic effects.However, the observation that hydrophilic statins have pleiotropic effects similar to those of lipophilic statins calls into question whether there are really any cholesterol-independent effects of statins.Indeed, recent evidence suggests that some of the cholesterol-independent effects of these agents may be mediated by inhibition of hepatic HMG-CoA reductase, leading to subsequent reduction in circulating isoprenoid levels (4).This hypothesis may help explain why hydrophilic statins such as pravastatin and rosuvastatin are still able to exert cholesterol-independent benefits on the vascular wall without directly entering vascular wall cells.In this respect, the word "pleiotropic" probably does not reflect the hepatic versus nonhepatic effects of these agents. Clinical trials with statinsBecause serum cholesterol level is strongly associated with coronary heart disease (5), it has been generally assumed that cholesterol reduction by statins is the predominant, if not the only, mechanism underlying their beneficial effects in cardiovascular diseases.However, subgroup analysis of large clinical trials such as the 4S, WOSCOP, CARE, and HPS suggests that the clinical benefits of statins are not associated with base-line cholesterol levels or the degree of cholesterol reduction (6-9).Furthermore, in angiographic trials, clinical improvements with statins far exceed changes in the size of atherosclerotic lesions (10).It is quite likely that cholesterol lowering in these longterm trials stabilized atherosclerotic plaques and made them less prone to rupture.However, in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial, statins reduced recurrent ischemic events within 16 weeks following acute coronary ischemia (11).Although the serum LDL-cholesterol was decreased by 40%, this time frame was probably far too rapid for appreciable changes in lesion size and plaque stability to occur as a consequence of cholesterol reduction.An intriguing but perplexing result of large clinical trials with statins is the reduction in ischemic stroke ( 12).Although myocardial infarction is closely associated with serum cholesterol levels, neither the Framingham Heart Study nor the Multiple Risk Factor Intervention Isoprenoids as mediators of the biological effects of statins
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the effects of statins are connected with the inhibition of the synthesis of important isoprenoids, e.g.farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are important lipid attachments for the γ subunit of heterotrimeric G-proteins [12] , guanosine triphosphatebinding protein Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap) [12][13][14] .”
From Statins as antifungal agents (2011) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Rho GTPases and signaling networksPreprint
Aelst, L. V., & D’Souza‐Schorey, C. (1997) · Genes & Development · doi:10.1101/gad.11.18.2295 · Cited by 2,358
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Flagged first, then by citations
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 101–200 of 355
Atorvastatin Induces T Cell Anergy via Phosphorylation of ERK1
Waiczies, S., Prozorovski, T., Infante‐Duarte, C., Hahner, A., Aktaş, O., Ullrich, O., & Zipp, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5630 · Cited by 63
Protein Prenylation and Synaptic Plasticity: Implications for Alzheimer’s Disease
Hottman, D. A., & Li, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8627-z · Cited by 65
PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation
Dou, X., Wei, J., Sun, A., Shao, G., Childress, C., Yang, W., & Lin, Q. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0178-0 · Cited by 62
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
Borgquist, S., Jögi, A., Pontén, F., Rydén, L., Brennan, D. J., & Jirström, K. (2008) · Breast Cancer Research · doi:10.1186/bcr2146 · Cited by 61
Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts
Schaafsma, D., McNeill, K. D., Mutawe, M. M., Ghavami, S., Unruh, H. W., Jacques, É., Laviolette, M., Chakir, J., & Halayko, A. J. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-113 · Cited by 59
Lipid Abnormalities and Renal Disease: Is Dyslipidemia a Predictor of Progression of Renal Disease?
Thallapureddy, A., Migdal, S. D., Crook, E. D., Flack, J. M., Salahudeen, A. K., Taylor, H. A., Greene, E. L., & Tucker, J. K. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200306000-00005 · Cited by 58
Okopień, B., Krysiak, R. G., Kowalski, J., Madej, A., Belowski, D., Zieliński, M., Łabuzek, K., & Herman, Z. S. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.05.009 · Cited by 58
Nishida, K., Yamamoto, T., Motomura, G., Jingushi, S., & Iwamoto, Y. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0189-4 · Cited by 57
Systematic review of the in vitro effects of statins on oral and perioral microorganisms
Ting, M., Whitaker, E. J., & Albandar, J. M. (2015) · European Journal Of Oral Sciences · doi:10.1111/eos.12239 · Cited by 57
Regulatory T cells: Possible mediators for the anti-inflammatory action of statins
Shahbaz, S. K., Sadeghi, M., Koushki, K., Penson, P. E., & Sahebkar, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104469 · Cited by 58
Takemoto‐Kimura, S., Terai, H., Takamoto, M., Ohmae, S., Kikumura, S., Segi‐Nishida, E., Arakawa, Y., Furuyashiki, T., Narumiya, S., & Bito, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300578200 · Cited by 55
Ongoing clinical trials of the pleiotropic effects of statins
Davignon, J., & Leiter, L. A. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.1.1.29.58937 · Cited by 51
Protein modification in aging: An update
Schöneich, C. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.07.002 · Cited by 54
The Effect of Rosuvastatin in a Murine Model of Influenza A Infection
Radigan, K. A., Urich, D., Misharin, A. V., Chiarella, S. E., Soberanes, S., Gonzalez, A., Perlman, H., Wunderink, R. G., Budinger, G. R. S., & Mutlu, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035788 · Cited by 53
Simon, M. S., Rosenberg, C. A., Rodabough, R. J., Greenland, P., Ockene, I. S., Roy, H. K., Lane, D. S., Cauley, J. A., & Khandekar, J. D. (2011) · Annals of Epidemiology · doi:10.1016/j.annepidem.2011.10.006 · Cited by 52
Estatinas e stresse oxidativo na insuficiência cardíaca crónica
Torres-Costa, S., Reina‐Couto, M., Albino‐Teixeira, A., & Sousa, T. (2016) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2015.09.006 · Cited by 53
Poliakov, E., Brennan, M., MacPherson, J. C., Zhang, R., Sha, W., Narine, L., Salomon, R. G., & Hazen, S. L. (2003) · The FASEB Journal · doi:10.1096/fj.03-0086com · Cited by 52
Desai, P. M., Chlebowski, R. T., Cauley, J. A., Manson, J. E., Wu, C., Martin, L. W., Jay, A. M., Bock, C. H., Coté, M. L., Petrucelli, N., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0562 · Cited by 49
Brennan, D. J., Brändstedt, J., Rexhepaj, E., Foley, M., Pontén, F., Uhlén, M., Gallagher, W. M., O’Connor, D. P., O’Herlihy, C., & Jirström, K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-125 · Cited by 49
Aprigliano, I., Dudás, J., Ramadori, G. P., & Saile, B. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01682.x · Cited by 48
Geluk, C. A., Asselbergs, F. W., Hillege, H. L., Bakker, S. J. L., de Jong, P. E., Zijlstra, F., & van Gilst, W. H. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi253 · Cited by 48
Statins as anti‐tumor agents: A paradigm for repurposed drugs
Tripathi, S., Gupta, E., & Galande, S. (2024) · Cancer Reports · doi:10.1002/cnr2.2078 · Cited by 52
Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation
Kim, W.-Y., Gonsiorek, E. A., Barnhart, C., Davare, M. A., Engebose, A. J., Lauridsen, H. M., Bruun, D. A., Lesiak, A. J., Wayman, G. A., Bucelli, R. C., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05854.x · Cited by 46
Statins and myocardial remodelling: cell and molecular pathways
Porter, K. E., & Turner, N. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001931 · Cited by 46
Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein
Chu, A. Y., Guilianini, F., Barratt, B. J., Nyberg, F., Chasman, D. I., & Ridker, P. M. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.961847 · Cited by 45
Lovastatin attenuates nerve injury in an animal model of Guillain–Barré syndrome
Sarkey, J. P., Richards, M. P., & Stubbs, E. B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04309.x · Cited by 44
Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer’s Disease
Li, L., Zhang, W., Cheng, S., Cao, D., & Parent, M. A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8253-1 · Cited by 48
Radcliffe, K. A., & Campbell, W. W. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0011-4 · Cited by 45
Role of statin therapy in the coronary bypass patient
Lazar, H. L. (2004) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2003.12.041 · Cited by 45
Qiu, G., & Hill, J. S. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318167141f · Cited by 44
Statin therapy of calcific aortic stenosis: hype or hope?
Liebe, V., Brueckmann, M., Borggrefe, M. M., & Kaden, J. J. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi697 · Cited by 44
Blankier, S. A., McCrindle, B. W., Ito, S., & Yeung, R. S. M. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04331.x · Cited by 43
Habis, M., Wroblewski, K., Bradaric, M. J., Ismail, N., Yamada, S. D., Litchfield, L. M., Lengyel, E. R., & Romero, I. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104521 · Cited by 43
Nakashima, Y., & Haneji, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072033 · Cited by 42
Michalik, M., Soczek, E., Kosińska, M., Rak, M., Wójcik‐Pszczoła, K., Lasota, S., Pierzchalska, M., Czyż, J., & Madeja, Z. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.023 · Cited by 42
Posada‐Duque, R., Velásquez-Carvajal, D., Eckert, G. P., & Cardona‐Gómez, G. P. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.026 · Cited by 41
Brinkkoetter, P.-T., Göttmann, U., Schulte, J. H., van der Woude, F. J., Braun, C., & Yard, B. A. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03217.x · Cited by 41
Konduracka, E., Galicka-Latała, D., Cieślik, G., Rostoff, P., Fedak, D., Sieradzki, J., Naskalski, J. W., & Piwowarska, W. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00798.x · Cited by 41
Dereli, Y., Ege, E., Kurban, S., Narin, C., Sarıgül, A., & Yeniterzi, M. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600611 · Cited by 40
Statins and oxidative stress in chronic heart failure
Costa, S., Reina‐Couto, M., Albino‐Teixeira, A., & Sousa, T. (2016) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2015.12.016 · Cited by 41
Zhang, X., Tao, Y., Wang, J., García‐Mata, R., & Markovic‐Plese, S. (2012) · European Journal of Immunology · doi:10.1002/eji.201242566 · Cited by 40
Shiomi, M., Koike, T., & Ito, T. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.030 · Cited by 40
Aktaş, O., Waiczies, S., & Zipp, F. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.026 · Cited by 40
Parent, M.-A. L. T., Hottman, D. A., Cheng, S., Zhang, W., McMahon, L. L., Yuan, L., & Li, L. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0051-z · Cited by 40
Shimabukuro‐Vornhagen, A., Zoghi, S., Liebig, T. M., Wennhold, K., Chemitz, J., Draube, A., Kochanek, M., Blaschke, F., Pallasch, C. P., Holtick, U., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1203436 · Cited by 38
Laumen, H., Skurk, T., & Hauner, H. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.06.005 · Cited by 39
Simvastatin affects cell motility and actin cytoskeleton distribution of microglia
Kuipers, H. F., Rappert, A., Mommaas, A. M., van Haastert, E. S., van der Valk, P., Boddeke, H. W. G. M., Biber, K. P. H., & van den Elsen, P. J. (2005) · Glia · doi:10.1002/glia.20269 · Cited by 39
Statins’ immunomodulatory potential against Th17 cell-mediated autoimmune response
Zhang, X., & Markovic‐Plese, S. (2008) · Immunologic Research · doi:10.1007/s12026-008-8019-z · Cited by 38
Isoprenylcysteine Carboxyl Methyltransferase Modulates Endothelial Monolayer Permeability
Lü, Q., Harrington, E. O., Hai, C.-M., Newton, J., Garber, M., Hirase, T., & Rounds, S. (2003) · Circulation Research · doi:10.1161/01.res.0000113923.85084.c1 · Cited by 38
Galgóczy, L., Papp, T., Lukács, G., Leiter, Ã., Pócsi, I., & Vágvölgyi, C. (2007) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2007.00661.x · Cited by 37
Orsoni, A., Thérond, P., Tan, R., Giral, P., Robillard, P., Kontush, A., Meikle, P. J., & Chapman, M. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p068585 · Cited by 37
Chen, X.-Y., Li, K., Light, A. R., & Fu, K. (2013) · Journal of Pain · doi:10.1016/j.jpain.2013.05.011 · Cited by 36
Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis
Eller, K., Eller, K., Wolf, A. M., Reinstadler, S. J., Tagwerker, A., Patsch, J. R., Mayer, G. J., & Rosenkranz, A. R. (2009) · Kidney International · doi:10.1038/ki.2009.478 · Cited by 36
Statins as Immunomodulators in Systemic Sclerosis
Abou‐Raya, A., Abou‐Raya, S., & Helmii, M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1423.070 · Cited by 35
Aydın, M. Ü., Aygül, N., Altunkeser, B. B., Ünlü, A., & Taner, A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.003 · Cited by 37
Lovastatin Induces Relaxation and Inhibits L‐Type Ca2+ Current in the Rat Basilar Artery
Bergdahl, A., Persson, E., Hellstrand, P., & Swärd, K. (2003) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2003.930304.x · Cited by 35
Roubey, R. A. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11332 · Cited by 35
Khan, S., Huda, B., Bhurka, F., Patnaik, R., & Banerjee, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178429 · Cited by 50
Hutchinson-Gilford progeria syndrome: Rejuvenating old drugs to fight accelerated ageing
Guilbert, S. M., Cardoso, D., Lévy, N., Muchir, A., & Nissan, X. (2020) · Methods · doi:10.1016/j.ymeth.2020.04.005 · Cited by 31
Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects
Kolawole, E. M., McLeod, J. J. A., Ndaw, V. S., Abebayehu, D., Barnstein, B. O., Faber, T., Spence, A. J., Taruselli, M. T., Paranjape, A. R., Haque, T. T., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501932 · Cited by 33
Vogel, T. J., Goodman, M. T., Li, A. J., & Jeon, C. Y. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.009 · Cited by 33
The cardioprotective effects of statins
Davignon, J. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0113-7 · Cited by 33
Circulating Monocytes and Plasma Inflammatory Biomarkers in Active Crohnʼs Disease
Grip, O., Janciauskiene, S. M., & Lindgren, S. C. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200405000-00003 · Cited by 33
Statins: Complex outcomes but increasingly helpful treatment options for patients
Mohammadkhani, N., Gharbi, S., Rajani, H. F., Farzaneh, A., Mahjoob, G., Hoseinsalari, A., & Korsching, E. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172704 · Cited by 37
An overview of statin-associated proteinuria
Tiwari, A. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.017 · Cited by 32
Muscle Symptoms Associated with Statins: A Series of Twenty Patients
Soininen, K., Niemi, M., Kilkki, E., Strandberg, T. E., & Kivist, K. T. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_193.x · Cited by 32
Hooff, G. P., Volmer, D. A., Wood, W. G., Müller, W. E., & Eckert, G. P. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2306-3 · Cited by 32
Inhibiting Ras Signaling in the Therapy of Breast Cancer
Li, T., & Sparano, J. A. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.005 · Cited by 31
How to balance cardiorenometabolic benefits and risks of statins
Lim, S. K., Oh, P. C., Sakuma, I., & Koh, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.001 · Cited by 31
The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations
Murlasits, Z., & Radak, Z. O. (2014) · Sports Medicine · doi:10.1007/s40279-014-0224-4 · Cited by 32
Buranrat, B., Mairuae, N., & Konsue, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.032 · Cited by 30
Li, X., & Zhou, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13559 · Cited by 31
Kotyla, P. J. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10384307 · Cited by 31
Statins in heart failure—With preserved and reduced ejection fraction. An update
Tousoulis, D., Oikonomou, E. K., Siasos, G., & Stefanadis, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.001 · Cited by 32
Timing of Administration: For Commonly-Prescribed Medicines in Australia
Kaur, G., Phillips, C. L., WONG, K. K. H., McLachlan, A. J., & Saini, B. (2016) · Pharmaceutics · doi:10.3390/pharmaceutics8020013 · Cited by 30
Emerging therapies for the prevention of acute respiratory distress syndrome
Ruthman, C. A., & Festić, E. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815585716 · Cited by 30
Elsayed, M. M., Kobayashi, D., Kubota, T., Matsunaga, N., Murata, R., Yoshizawa, Y., Watanabe, N., Matsuura, T., Tsurudome, Y., Ogino, T., et al. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00746 · Cited by 30
Han, B., Alonso-Valenteen, F., Wang, Z., Deng, N., Lee, T.-Y., Gao, B., Zhang, Y., Xu, Y., Zhang, X., Billet, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.07.003 · Cited by 31
Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS
Chhonker, Y. S., Haney, S. L., Bala, V., Holstein, S. A., & Murry, D. J. (2018) · Molecules · doi:10.3390/molecules23123275 · Cited by 30
Lipid-modified proteins as biomarkers for cardiovascular disease: a review
Ferri, N., Paoletti, R., & Corsini, A. (2005) · Biomarkers · doi:10.1080/13547500500216660 · Cited by 30
Statins: immunomodulators for autoimmune rheumatic disease?
Jury, E. C., & Ehrenstein, M. R. (2005) · Lupus · doi:10.1191/0961203303lu2135oa · Cited by 30
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients
Koksal, M., Eren, M. A., Turan, M. N., & Sabuncu, T. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.12.003 · Cited by 29
Schiefelbein, D., Goren, I., Fißlthaler, B., Schmidt, H., Geißlinger, G., Pfeilschifter, J. M., & Frank, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709841200 · Cited by 29
Okopień, B., Krysiak, R. G., Haberka, M., & Herman, Z. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000156821.50457.32 · Cited by 29
Fuentes-Fayos, A. C., García‐Martínez, A., Herrera-Martínez, A. D., Jiménez‐Vacas, J. M., Vazquez-Borrego, M. C., Castano, J. P., Pico, A. M., Gahete, M. D., & Luque, R. M. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.02970-5 · Cited by 28
The Effect of Statin on Epithelial-Mesenchymal Transition in Peritoneal Mesothelial Cells
Chang, T. I., Kang, H.-Y., Kim, K. S., Lee, S. H., Nam, B. Y., Paeng, J., Kim, S., Park, J. T., Yoo, T., Kang, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109628 · Cited by 28
KONES, R. J. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709337056 · Cited by 29
Markovic‐Plese, S., Singh, A. K., & Singh, I. (2008) · Future Neurology · doi:10.2217/14796708.3.2.153 · Cited by 28
Jaśkiewicz, A., Pająk, B., Litwiniuk, A., Urbańska, K., & Orzechowski, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6463807 · Cited by 28
Can statins put the brakes on Alzheimer’s disease?
Whitfield, J. F. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1479 · Cited by 28
Brennan, D. J., Laursen, H., O’Connor, D. P., Borgquist, S., Uhlén, M., Gallagher, W. M., Pontén, F., Millikan, R. C., Rydén, L., & Jirström, K. (2011) · Breast Cancer Research · doi:10.1186/bcr2820 · Cited by 27
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 24
Red mold fermented products and Alzheimer's disease: a review
Lee, C.-L., & Pan, T. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3413-1 · Cited by 28
Statin therapy in heart failure: Prognostic effects and potential mechanisms
Shanes, J. G., Minadeo, K. N., Moret, A., Groner, M., & Tabaie, S. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.05.020 · Cited by 27
Impact of statin use on cancer-specific mortality and recurrence
Yang, J., Li, C., Shen, Y., Zhou, H., Shao, Y., Zhu, W., & Chen, Y. (2020) · Medicine · doi:10.1097/md.0000000000019596 · Cited by 27
Schroeter, M. R., Humboldt, T., Schäfer, K., & Konstantinides, S. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.11.013 · Cited by 26
Massari, C. M., de Castro, A. A., Dal-Cim, T. A., Lanznaster, D., & Tasca, C. I. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.09.015 · Cited by 26
Rudofsky, G., Reismann, P., Groener, J. B., Djuric, Z., Fleming, T. H., Metzner, C., Grafe, I., Bierhaus, A., & Nawroth, P. P. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.003 · Cited by 26
Meyers, C. D., Tannock, L. R., Wight, T. N., & Chait, A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300252-jlr200 · Cited by 26
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0428-4 · Cited by 25
Metadata
- Authors
- Liao, J. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Liao, James K.
- ORCID
- Liao, James K.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-08-01
- Volume
- 110
- Issue
- 3
- Pages
- 285-288
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4235797558
- Cited by
- 352
- References
- 35
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 16 · 2013: 13 · 2012: 16
- FWCI
- 23.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, terpenoids, pleiotropy, cholesterol-independent effects, HMG-CoA reductase inhibition, cholesterol biosynthesis, isoprenylation, small GTPases, Rho, Ras, Rac, endothelial function, atherosclerotic plaque stability, oxidative stress, inflammation, thrombogenicity, statin adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
